Healthcare Industry News: MicroPort Navibot
News Release - December 1, 2022
MicroPort MedBot NaviBot Announces First Clinical Use of Skywalker(TM) Surgical Robot for Total Knee ProceduresFOXBOROUGH, Mass., Dec. 1, 2022 -- (Healthcare Sales & Marketing Network) -- Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort MedBot") announced that on November 22nd, 2022 MicroPort Navibot International, LLC in recent collaboration with MicroPort Orthopedics has completed the first clinical use of the SkyWalker™ Robotic System in the United States. Dr. Joseph Kavolus, of Lighthouse Surgical Suites in Hollis, N.H., conducted the successful procedure. Dr. Kavolus specializes in orthopedic surgery and the treatment of orthopedic injuries.
"The design of the Evolution® Medial-Pivot knee makes me a better surgeon, regardless of my alignment philosophy and, as a new user, I couldn't be happier to provide this to my patients," Kavolus stated. "For the first case with a new technology, I was pleasantly surprised at the smooth flow and execution, ease of integration into my workflow, and thrilled that the outcome was exceptional."
The organization has now moved into its limited market release and intends to ramp up its site locations. MicroPort MedBot also intends to integrate new applications on its platform including Hip replacement as a next application in early 2024.
About MicroPort Navibot
MicroPort Navibot International LLC is located in Foxborough, Massachusetts ("NaviBot"). NaviBot develops, manufactures, and markets comprehensive hard tissue robotic assisted surgical solutions. The SkyWalker™ Surgical Robotic System for the total knee is its 1st approved application, provides surgeons enhanced capability of customized preoperative planning and accurate intraoperative robotic assistance during total knee arthroplasty.
MicroPort Navibot International LLC is a subsidiary of NaviBot (Suzhou) Co., Ltd. (hereinafter referred to as " NaviBot Suzhou").
NaviBot Suzhou starts from the clinical needs of hard tissue surgery, explores key technologies, and is committed to developing minimally invasive, accurate and efficient hard tissue robotic products.
The SkyWalker™ surgical robot is an FDA cleared system of MicroPort Navibot International LLC. The Evolution® Knee System is owned by MicroPort Orthopedics.
About MicroPort MedBot
Commenced its development for laparoscopic surgery robots in 2014, and officially established in Shanghai in 2015, Shanghai MicroPort MedBot (Group) Co., Ltd. ("MicroPort MedBot", stock code: 02252.HK), a subsidiary of MicroPort Scientific Corporation ("MicroPort", stock code: 00853.HK), is currently the only surgical robot company in the world with businesses covering five promising subsectors of surgical robots, including endoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture. At MicroPort MedBot, we are committed to meeting the growing demand for cutting-edge robotic surgery. By integrating advanced research on robotics, control algorithms, image-based navigation, and precision imaging, we provide comprehensive intelligent surgical solutions to prolong and reshape the lives of patients, lead the advancement of robotic surgery, and shape the era of intelligent surgery.
More information is available at www.medbotsurgical.com/en/.
Source: MicroPort Orthopedics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.